|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1.
|
16155208 |
2005 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
1,1-Bis(3'indolyl)-1-(p-substitutedphenyl)methanes containing p-trifluoromethyl (DIM-C-pPhCF)), p-t-butyl (DIM-C-pPhtBu), and p-phenyl (DIM-C-pPhC6H5) groups induce peroxisome proliferator-activated receptor gamma (PPARgamma)-mediated transactivation in HT-29, HCT-15, RKO, and SW480 colon cancer cell lines.
|
15342379 |
2004 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR-gamma), a member of the nuclear hormone receptor superfamily, is involved in suppression of growth of several types of tumors such as liposarcoma, breast cancer, prostate cancer, and colon cancer, possibly through induction of cell cycle arrest and/or apoptosis.
|
11494023 |
2001 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the nuclear receptor superfamily, plays a role in adipocyte differentiation, type II diabetes, macrophage response to inflammation and is suggested to influence carcinogen-induced colon cancer.
|
15073042 |
2004 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Based on our findings, p38 MAPK and transcription factor PPARgamma can be considered as molecular targets of resveratrol in the regulation of cell proliferation and SSAT activity, respectively, in a cell culture model of colon cancer.
|
16849586 |
2006 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists.
|
30931956 |
2019 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Comparison of the transcriptome data of metastasis-competent CTC-MCC-41 cells and of HT-29 cells (derived from a primary colon cancer) highlights the differential expression of genes that regulate energy metabolism [peroxisome proliferator-activated receptor γ coactivator 1A (<i>PPARGC1A</i>), peroxisome proliferator-activated receptor γ coactivator 1B (<i>PPARGC1B</i>), fatty acid binding protein 1 (<i>FABP1</i>), aldehyde dehydrogenase 3 family member A1 (<i>ALDH3A1</i>)], DNA repair [BRCA1 interacting protein C-terminal helicase 1 (<i>BRIP1</i>), Fanconi anemia complementation group B (<i>FANCB</i>), Fanconi anemia complementation group M (<i>FANCM</i>)], and stemness [glutaminase 2 (<i>GLS2</i>), cystathionine-beta-synthase (<i>CBS</i>), and cystathionine gamma-lyase (<i>CTH</i>)].
|
28007957 |
2017 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression of this protein may prevent PPARgamma ligand efficiency in colon cancer treatment.
|
17611675 |
2007 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally, EPA suppressed HT-29 cell growth and this effect was significantly reversed by the addition of GW, suggesting that in part the physiological actions of EPA are the result of PPARgamma activation.
|
18203887 |
2008 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
For in vivo studies, 1,2-dimethylhydrazine dihydrochloride (DMH) was s.c. injected to induce colon cancer in PPARgamma(+/+) and PPARgamma(+/-) mice.
|
19458067 |
2009 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
High lutein intake [odds ratio (OR), 0.63; 95% confidence interval (95% CI), 0.44-0.89], low refined grain intake (OR, 0.70; 95% CI, 0.53-0.94), or a high prudent diet score (OR, 0.66; 95% CI, 0.49-0.89) and PA/AA PPARgamma genotype were associated with reduced colon cancer risk.
|
15894676 |
2005 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, only retroviral transduction of the wild-type (WT), but not mutant, receptor could restore PPARgamma ligand-induced growth inhibition and differentiation in resistant colon cancer cell lines.
|
12591919 |
2003 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, PPARgamma protein levels are elevated, possibly through sequestration by activated beta-catenin in colon cancer cell lines.
|
15665104 |
2005 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, FPLD3-associated PPARγ mutations consistently cause intra- and/or intermolecular defects; colon cancer-associated PPARγ mutations on the other hand may play a role in colon cancer onset and progression, but this is not due to their effects on the most well-studied functional characteristics of PPARγ.
|
30595551 |
2019 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, SOX9, β-catenin and PPARγ expression levels are deregulated in the CRC tissue, and in colon cancer cell lines ligand-dependent PPARγ activation unevenly influences SOX9 and β-catenin expression and subcellular localization, suggesting a variable mechanistic role in colon carcinogenesis.
|
23583560 |
2013 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone.
|
14634802 |
2004 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interactions between PPAR Gamma and the Canonical Wnt/Beta-Catenin Pathway in Type 2 Diabetes and Colon Cancer.
|
28298922 |
2017 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines.
|
19551868 |
2009 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that PPARgamma plays a role as a physiological regulator of colonic epithelial cell turnover and consequently predisposition to the development of colon cancer in early stage.
|
18391483 |
2008 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor (PPAR) gamma is expressed in human colon cancer, prostate cancer and breast cancer cells, and PPARgamma activation induces growth inhibition in these cells.
|
11044367 |
2000 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Stratified meta-analysis indicated that PPAR-gamma 34 C>G was associated with colon cancer (OR = 0.8, 95% CI: 0.65-0.99, P = 0.04) in random-effect model, and the G allele decreased colon cancer risk.
|
20440859 |
2010 |
|
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The activation of peroxisome proliferator-activated receptor gamma stimulated by thiazolidinedione is useful in the treatment of type II diabetes mellitus and may have value in preventing inflammatory bowel disease or colon cancer.
|
12946210 |
2003 |
|
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The molecules and signals that act to eradicate or initiate the apoptosis cascade in cancer cells, are elucidated, and these include caspases, Fas, Bax, Bid, APC, antisense hTERT, PUMA, 15-LOX-1, ceramide, butyrate, tributyrin and PPARgamma, whereas the molecules which promote colon cancer cell survival are p53 mutants, Bcl-2, Neu3 and COX-2.
|
15255176 |
2004 |
|
Malignant tumor of colon
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The odd ratio for PPARgamma PA or AA genotype relative to the PP genotype for colon cancer was 0.9 (95% confidence interval, CI=0.8-1.0) and for rectal cancer was 1.2 (95% CI=1.0-1.5) adjusting for race, age, and sex.
|
15860437 |
2005 |